Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc has appointed three new cardiovascular experts to its Scientific Advisory Board.
The clinical-stage life sciences company welcomed Dr Paul Ridker, Dr Bruce McManus and Dr Joseph A Hill to the board.
READ: Cardiol Therapeutics raises US$50M to advance research and clinical development initiatives
Ridker is the director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women's Hospital in Boston and the Eugene Braunwald Professor of Medicine at Harvard School of Medicine.
His clinical focus includes coronary artery disease and the underlying causes and prevention of atherosclerotic disease, and his research has involved inflammatory mediators of heart disease and the molecular and genetic epidemiology of hemostasis and thrombosis, with particular interests in biomarkers for coronary disease, "predictive" medicine, and the underlying causes and prevention of atherosclerotic disease.
McManus is a Professor Emeritus at the Department of Pathology and Laboratory Medicine, the University of British Columbia. He has served as CEO at the Centre of Excellence for Prevention of Organ Failure (PROOF Centre); Director at the UBC Centre for Heart Lung Innovation, and Scientific Director, Institute of Circulatory and Respiratory Health, CIHR.
Hill is a professor of Internal Medicine and Molecular Biology, Chief of Cardiology at UT Southwestern Medical Center in Dallas, and Director of the Harry S Moss Heart Center. Hill's research examines molecular mechanisms of structural, functional, metabolic, and electrophysiological remodeling in cardiac hypertrophy and heart failure.
"We are pleased to welcome distinguished thought leaders in cardiovascular medicine to our Scientific Advisory Board," said David Elsley, CEO of Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL). "Their expertise in cardiovascular research will provide invaluable guidance to our research and clinical programs focused on the development of novel anti-inflammatory therapies for the treatment of heart disease."
Oakville, Ontario-based Cardiol is focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease. Its lead product, CardiolRx, is an oral cannabidiol formulation pharmaceutically manufactured under cGMP that is being investigated in a Phase II/III outcomes study.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas